Kanamycin promotes biofilm viability of MRSA strains showing extremely high resistance to kanamycin.

MLST S. aureus SCCmec antibiotics stress biofilm

Journal

Microbial pathogenesis
ISSN: 1096-1208
Titre abrégé: Microb Pathog
Pays: England
ID NLM: 8606191

Informations de publication

Date de publication:
29 Sep 2024
Historique:
received: 22 05 2024
revised: 20 08 2024
accepted: 28 09 2024
medline: 3 10 2024
pubmed: 3 10 2024
entrez: 1 10 2024
Statut: aheadofprint

Résumé

Staphylococcus aureus is widely distributed in environment and can cause various human infection and food poisoning cases. Also, this pathogen is a typical biofilm former, which further complicates its pathogenicity. Antibiotics have been widely used to eliminate pathogenic bacteria, but their indiscriminate use has also led to the widespread emergence of drug-resistant bacteria, such as Methicillin-Resistant Staphylococcus aureus (MRSA). In this study, the effect of antibiotics on biofilm formation of MRSA strains 875 and 184 was explored. Firstly, MRSA 875 belongs to SCCmec type IV, ST239, carrying the atl, icaA, icaD, icaBC, and aap genes, and MRSA 184 belongs to SCCmec type II, ST5, carrying the atl, icaD, icaBC, aap, and agr genes. Then, a total of 8 antibiotics have been selected, including kanamycin, gentamycin, cipprofloxacin, erythromycin, meropenem, penicillin G, tetracycline, vancomycin. Minimum inhibitory concentrations (MICs) of each antibiotic were determined, and MIC of MRSA 875 and 184 to kanamycin/gentamicin are 2048/64 μg/mL and 2048/4 μg/mL, respectively. A total of 10 concentrations, ranging from 1/128 to 4 MIC with 2-fold, were used to study biofilm formation. Biofilm biomass and viability were determined during different phases, including initial adhesion (8 h), proliferation (16 h), accumulation (24 h) and maturation (48 h). Importantly, kanamycin at specific concentrations showed significant promotion of biofilm biomass and biofilm viability, with none of such observation acquired from other antibiotics. This study provides scientific basis and new research ideas for the quality control technology of microorganisms and safety prevention of MRSA.

Identifiants

pubmed: 39353484
pii: S0882-4010(24)00453-4
doi: 10.1016/j.micpath.2024.106986
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106986

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest: none.

Auteurs

Guangchao Yu (G)

Center of Clinical Laboratory Medicine, First Affiliated Hospital of Jinan University, Guangzhou, China; Shunde Hospital of Guangzhou University of Chinese Medicine, Foshan, China.

Teng Yi Huang (TY)

Department of Diagnostics, Second Affiliated Hospital of Shantou University Medical College, Shantou, China. Electronic address: tyh27704@163.com.

Yu Li (Y)

Department of Pathology, Qiqihar Medical University, Qiqihar, China.

Classifications MeSH